Usually, non-severe remittent disease progresses slowly and most of them have a good prognosis. The cure rate for severe remittent anemia treated with bone marrow transplantation is 60% to 80%, and the exact cure rate varies from person to person. Aplastic anemia is a disease of bone marrow hematopoietic failure caused by chemical (benzene, chloramphenicol, etc.), physical (radiation), biological factors or unknown causes, characterized by decreased proliferation of bone marrow hematopoietic cells and decreased peripheral blood plasma cells, and the bone marrow is free of abnormal cellular infiltration and reticulofibrillar proliferation, and the clinical manifestations include anemia, hemorrhage, and infection. Hematopoietic stem cell transplantation is a potentially curative treatment for aplastic anemia. The 5-year survival rate of severe aplastic anemia can be more than 80% when treated with HLA-compatible sibling HSCT, and the life expectancy of patients who have survived for more than 5 years is not significantly different from that of normal people of the same age and sex. Patients treated with hematopoietic stem cell transplantation from an unrelated donor also have an outcome of about 60%. Complications such as serious infections (e.g. bacterial, fungal, viral, etc.), bleeding (intracranial bleeding, gastrointestinal bleeding, etc.) can lead to death at any time during treatment. It is recommended that patients consult the Department of Hematology in a timely manner to develop an individualized treatment plan based on their specific condition, and the cure rate will be evaluated by a specialist based on their condition and treatment efficacy.